AllianceBernstein’s Climb Bio CLYM Stock Holding History

AllianceBernstein’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$217K	Buy	+31,670	New	+$327K	﹤0.01%	3117

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AllianceBernstein's CLYM Position: Q2 2026 in Review

AllianceBernstein opened a new position in Climb Bio (CLYM) in Q2 2026: 31,670 shares worth $217K. The stake represents ﹤0.01% of the portfolio and ranks #3117 among its holdings.

109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

AllianceBernstein held 31,670 shares of Climb Bio worth $217K as of Q2 2026.
Climb Bio was a new AllianceBernstein position in Q2 2026.
Climb Bio made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #3117 holding.
109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.